PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.

Safe dividend-paying income stocks trading under $30 are passive income home runs. Stocks trading under the $30 level offer Boomers a larger share count when they buy. With the geopolitical ...

Pfizer is undervalued as markets fixate on its patent cliff, overlooking strong cash flows, pipeline upside, and a 7% yield.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated ...

Vyndaqel’s gathering momentum – coupled with a 25% increase in sales of Pfizer’s breast cancer therapy Ibrance (palbociclib) to $1.28 billion – helped Pfizer post better-than-expected ...

NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if the pharma decides to drop its price.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an ‘Outperform’ rating and a $49 price target.

The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF. - Part 6 ...

In the case of Vyndaqel, Pfizer believes it may secure extensions to 2028, but that drug also faces competition from a couple of new market entrants i.e. BridgeBio's Attruby, and Alnylam's Amvuttra.

Nonetheless, drugs like Vyndaqel, Padcev and Eliquis, and newly acquired products should continue to drive top-line growth. BMY’s efforts to revive the top line in the face of generic challenges ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology ...